MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder CancerZacks Investment Research • 06/25/26
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline MaintenanceBusiness Wire • 06/24/26
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait24/7 Wall Street • 06/23/26
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with AnalystsBusiness Wire • 06/23/26
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung CancerBusiness Wire • 06/22/26
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow24/7 Wall Street • 06/22/26
Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This InsteadThe Motley Fool • 06/22/26
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?The Motley Fool • 06/20/26
Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 OutlookThe Motley Fool • 06/18/26